Skip to main content

Table 2 Efficacy outcomes.

From: Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study

  FPV Cohort (n = 105) SQV Cohort (n = 98)
% viral failure 22% 13%
Mean time of follow-up (months) 10.5 9.6
Mean CD4 count increase* +84 cells/mm3 +12 cells/mm3
  1. *In those subjects with 48 week data available (n = 36 and 26 for FPV and SQV cohorts, respectively).